// April 18, 2024
USP’s commitment to ESG considerations for a healthier, more sustainable world
At the U.S.
At the U.S.
The development of generic versions of innovator medicines is a global public health need.
To help strengthen the pharmaceutical supply chain and guard against potential shortages that can
With significant innovations in pharmaceuticals, including biologic drugs